These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19176031)

  • 21. [Relationship between RAD51-g135C and XRCC3-C241T polymorphisms and prognosis of inv (16)/ t(16;16) (CBFbeta-MYH11) acute myeloid leukemia].
    Liu L; Yang L; Mi YC; Li JY; Qin TJ; Xu ZF; Zhang Y; Wang JX; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):433-8. PubMed ID: 22213860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
    Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
    Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia.
    Auewarakul CU; Lauhakirti D; Promsuwicha O; Munkhetvit C
    Ann Hematol; 2006 Feb; 85(2):108-12. PubMed ID: 16320053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical and experimental characteristics of 20 patients with acute myeloid leukemia with complex variant of t(8; 21)].
    Xia J; Chen SN; Pan JL; Wang QR; Wu YF; Wang Y; Zhang J; Shen J; Xue YQ; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):815-20. PubMed ID: 23998566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FLT3-internal tandem duplication in a pediatric patient with t(8;21) acute myeloid leukemia.
    Kawamura M; Kaku H; Ito T; Funata N; Taki T; Shimada A; Hayashi Y
    Cancer Genet Cytogenet; 2010 Dec; 203(2):292-6. PubMed ID: 21156247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome.
    Lin P; Luthra R; Nussenzveig RH; Medeiros LJ
    Hum Pathol; 2010 May; 41(5):758-62. PubMed ID: 20153505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
    Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
    Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
    Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.
    Pich A; Riera L; Sismondi F; Godio L; Davico Bonino L; Marmont F; Francia di Celle P
    J Clin Pathol; 2009 Sep; 62(9):798-801. PubMed ID: 19734476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
    Ohanian M; Bueso-Ramos C; Ok CY; Lin P; Patel K; Alattar ML; Khoury JD; Rozovski U; Estrov Z; Huh YO; Cortes J; Abruzzo LV
    Cancer Genet; 2015 Nov; 208(11):571-4. PubMed ID: 26382622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.
    Beghini A; Ripamonti CB; Cairoli R; Cazzaniga G; Colapietro P; Elice F; Nadali G; Grillo G; Haas OA; Biondi A; Morra E; Larizza L
    Haematologica; 2004 Aug; 89(8):920-5. PubMed ID: 15339674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report.
    Asou C; Sakamoto T; Suzuki K; Okuda I; Osaki A; Abe R; Ito Y; Kakegawa E; Miyakawa Y; Terui Y; Nakamura Y
    J Med Case Rep; 2024 Aug; 18(1):372. PubMed ID: 39154170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and clinicopathologic characterization of AML with isolated trisomy 4.
    Bains A; Lu G; Yao H; Luthra R; Medeiros LJ; Sargent RL
    Am J Clin Pathol; 2012 Mar; 137(3):387-94. PubMed ID: 22338050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.
    Roug AS; Nyvold CG; Juhl-Christensen C; Christensen M; Schnittger S; Hokland P
    Eur J Haematol; 2011 Nov; 87(5):461-3. PubMed ID: 21689158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2 acute myelogenous leukemia].
    Shen YM; Chao HY; Zhang R; Li WY; Feng YF; Zhu ZL; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):366-70. PubMed ID: 19799086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
    Lück SC; Russ AC; Du J; Gaidzik V; Schlenk RF; Pollack JR; Döhner K; Döhner H; Bullinger L
    Br J Haematol; 2010 Mar; 148(6):925-37. PubMed ID: 20064158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.